Cardioprotection: Definition, classification, and fundamental principles

Heart

Volumn 75, Issue 4, 1996, Pages 330-333

  Kübler, Wolfgang ^a   Haass, Markus ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0030013805     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.75.4.330     Document Type: Short Survey

References (29)

1. Feigl EO. Coronary physiology. Physiol Rev 1983;63: 1-205.
2. Fabel H, Lübbers DW, Rybak R. Die Bestimmung des Myoglobingehaltes und des kritischen Sauerstoffdruckes am schlagenden Kaninchenherzen "in situ" [abstract]. Pflüger's Arch Physiol 1964;279:R32.
3. Kübler W. Tierexperimentelle Untersuchungen zum Myokardstoffwechsel im Angina-Pectoris-Anfall und beim Herzinfarkt. Bibliotheca Cardiologica No. 22. Basel, New York: S Karger, 1969:1-93.
4. Kübler W, Spieckermann PG. Changes in glycolysis and high energy phosphates during myocardial ischemia with intermittent coronary perfusion. Cardiology 1971;56: 100-7.
5. Kübler W, Spieckermann PG. Regulation of glycolysis in the ischemic and the anoxic myocardium. J Mol Cell Cardiol 1970;1:351-77.
6. Tauchert M. Koronarreserve und maximaler Sauerstoffverbrauch des menschlichen Herzens. Basic Res Cardiol 1973;68:183-223.
7. Starke K. Presynaptic receptors. Annu Rev Pharmacol Toxicol 1981;21:7-30.
8. Richardt G, Waas W, Kranzhöfer R, Mayer E, Schömig A. Adenosine inhibits exocytotic release of endogenous noradrenaline in rat heart: a protective mechanism in early myocardial ischemia. Circ Res 1987;61:117-23.
9. Harden TK. Agonist-induced desensitization of the beta-adrenergic receptor-linked adenylate cyclase. Pharmacol Rev 1983;35:5-32.
10. Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol 1993;22(suppl A): 61A-71A.
11. Feldman AM, Cates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL, et al. Increase of the 40 000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest 1988;82:189-97.
12. Neumann J, Schmitz W, Scholz H, von Meyerinck L, Döring V, Klamar P. Increase of myocardial Gi-proteins in human heart failure. Lancet 1988;ii:936-7.
13. Dart AM, Schömig A, Dietz R, Mayer E, Kübler W. Release of endogenous catecholamines in the ischaemic myocardium of the rat. Part B: effect of sympathetic nerve stimulation. Circ Res 1984;55:702-6.
14. Kübler W, Strasser RH. Signal transduction in myocardial ischemia. Eur Heart J 1994;15:437-45.
15. Lawson CS, Downey JM. Preconditioning: state of the art myocardial protection. Cardiovasc Res 1993;27:542-50.
16. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-36.
17. Rector TS, Cohn JN. Prognosis in congestive heart failure. Anna Rev Med 1994;45:341-50.
18. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
19. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham heart study. Am J Cardiol 1987;60:560-5.
20. Hammermeister KE, DeRouen TA, Dodge HT. Variables predictive of survival in patients with coronary disease: selection by univariate and multivariate analyses from clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. Circulation 1979;59:421-30.
21. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Circulation 1990;81:1161-72.
22. Rahimtoola SH. The hibernating myocardium. Am Heart J 1989;117:211-21.
23. Bretschneider HJ, Gebhard MM, Gersing E, Preusse CJ, Schnabel PhA. Recent advances for myocardial protection. In: Kaplitt MJ, Borman JB, eds. Concepts and controversies in cardiovascular surgery. Norwalk, CT: Appleton-Century-Crofts, 1983:174-85.
24. Cohn JN, Archibald DG, Phil M, Ziesche S, Franciosa JA, Harston WE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure - results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-52.
25. Cohn J, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazineisosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl JMed 1991;325:303-10.
26. Story DF, Ziogas J. Interaction of angiotensin with noradrenergic neuroeffector transmission. Trends Pharmacol Sci 1987;8:269-71.
27. Packer M, Bristow MR, Cohn EN, Colucci WS, Fowler MB, Gilbert EM. Effect of carvedilol on the survival of patients with chronic heart failure (abstract). Circulation 1995;92 suppl:I-142.
28. Rauch B, Kübler W. Antianginal medication. Current Opinion in Cardiology 1991;6:511-23.
29. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986;57:43F-9F.